Soligenix (SNGX) Receivables - Net (2010 - 2024)
Soligenix's (SNGX) quarterly Receivables - Net came in at $117029.0 in Q1 2024, down 46.32% YoY from $218008.0 in Q2 2023, and up 389.78% on a QoQ basis from $23894.0 in Q4 2023.
Soligenix (SNGX) Receivables - Net (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of Receivables - Net data on file, last reported at $117029.0 in Q1 2024.
- Quarterly Receivables - Net fell 46.32% year-over-year to $117029.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $117029.0 (down 46.32% YoY) and the FY2023 annual result came in at $23894.0, down 79.25% from the prior year.
- Receivables - Net grew to $117029.0 in Q1 2024, from $23894.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $841368.0 in Q1 2020 to a low of $22852.0 in Q3 2023.
- A 5-year average of $190214.1 and a median of $117029.0 in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2021 — Receivables - Net sank 88.8% — and 2022, when it jumped 195.9%.
- Tracing SNGX's Receivables - Net over 5 years: stood at $361096.0 in 2020, then sank by 71.25% to $103832.0 in 2021, then increased by 10.88% to $115130.0 in 2022, then tumbled by 79.25% to $23894.0 in 2023, then jumped by 389.78% to $117029.0 in 2024.
- The last three Receivables - Net figures came in at $117029.0 (Q1 2024), $23894.0 (Q4 2023), and $22852.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - |
| 10 | Soligenix | 6.30 Mn | 6.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 117,029.00 |
| Mar 31, 2024 | 117,029.00 |
| Dec 31, 2023 | 23,894.00 |
| Dec 31, 2023 | 23,894.00 |
| Sep 30, 2023 | 22,852.00 |
| Sep 30, 2023 | 22,852.00 |
| Jun 30, 2023 | 25,284.00 |
| Jun 30, 2023 | 25,284.00 |
| Mar 31, 2023 | 218,008.00 |
| Mar 31, 2023 | 218,008.00 |
| Dec 31, 2022 | 115,130.00 |
| Dec 31, 2022 | 115,130.00 |
| Sep 30, 2022 | 130,742.00 |
| Sep 30, 2022 | 130,742.00 |
| Jun 30, 2022 | 109,017.00 |
| Jun 30, 2022 | 109,017.00 |
| Mar 31, 2022 | 123,692.00 |
| Mar 31, 2022 | 123,692.00 |
| Dec 31, 2021 | 103,832.00 |
| Dec 31, 2021 | 103,832.00 |